LUHUA WANG to Pyrazoles
This is a "connection" page, showing publications LUHUA WANG has written about Pyrazoles.
Connection Strength
1.806
-
Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma. Sci Signal. 2019 02 05; 12(567).
Score: 0.349
-
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017 11 02; 10(1):171.
Score: 0.320
-
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. 2015 May; 97(5):455-68.
Score: 0.267
-
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun; 26(6):1175-1179.
Score: 0.265
-
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 08; 369(6):507-16.
Score: 0.236
-
Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. Expert Rev Clin Immunol. 2013 Jun; 9(6):495-7.
Score: 0.235
-
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56.
Score: 0.070
-
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9).
Score: 0.064